Health · Pharma & Biotech · 2 hrs ago
AstraZeneca blames trial design for failed bone disease drug study
AstraZeneca's Phase 3 trial of an enzyme replacement therapy for a genetic bone disease did not meet its goals.
The company says the trial design contributed to the failure.
Phase 3 trials test treatments in a later stage of clinical research.
The therapy is intended to replace an enzyme in people with the genetic bone disease.
The available details do not name the disease or explain which parts of the trial design were at issue.
They also do not say what AstraZeneca plans to do next.
Endpoints News reports that AstraZeneca’s Phase 3 trial of an enzyme replacement therapy for a genetic bone disease failed.
The headline says AstraZeneca blames the trial design for the failure.
The available article text says new details suggest the test missed its goals, but the excerpt ends before explaining why.
The article does not name the drug or the bone disease.
- Who
- AstraZeneca.
- What
- Its Phase 3 trial of an enzyme replacement therapy for a genetic bone disease failed.
- When
- October 11, 2026.
- Where
- Not stated.
- Why
- AstraZeneca blames the trial design, but the available article text does not give further details.
This story does not have two clearly opposing sides.
No direct quotes in the coverage so far.
This story does not have a timeline yet.
- Company
- AstraZeneca
- Trial phase
- Phase 3
- Treatment
- Enzyme replacement therapy
- Condition
- Genetic bone disease
- Reported date
- October 11, 2026
Sources
Related news
Experimental injection reduced visceral fat by 12% in early trials
Baby Sleep Gripe Water Recalled After Alcohol Found in Testing
FDA Warns Amazon Over Unapproved Herpes Treatments
Possible Wrong Dose Raises Questions for PDE9 Drug Trials in Heart Failure
FDA approves atezolizumab with chemotherapy for some stage III colon cancers
Review links drug company gifts to more and less appropriate prescribing
Brazil suspends Peptistrong supplement and orders all batches recalled
Experimental eye drops improve vision in a small study of a rare eye disease
Taboos limit sales of weight-loss drugs in India despite obesity rates
Roche reports year-long results for eye drug Vamikibart
